US Corporate Distress Financial Stress SEC Filings — June 09, 2026

09-06-2026

GSK plc announced a definitive agreement to acquire Nuvalent, Inc. for $10.6 billion ($124 per share in cash), representing a 40% premium to the last closing price. The deal includes two late-stage, potential best-in-class ROS1 (zidesamtinib) and ALK (neladalkib) inhibitors for non-small cell lung cancer currently under FDA review with target decision dates in September and November 2026, plus a phase I HER2 inhibitor (NVL-330). The acquisition is expected to be accretive to sales and core operating profit in 2027 and core EPS in 2029, but will cause low single-digit percentage dilution to core EPS for FY 2026, FY 2027, and FY 2028.

• · The transaction is expected to close in Q3 2026, subject to tender of a majority of Nuvalent's Class A shares and HSR Act clearance.
• · GSK will assume Nuvalent's existing revenue-sharing arrangements of low-single-digit royalties payable to Royalty Pharma and Deerfield.
• · The acquisition will be funded primarily from new and existing debt facilities plus cash, with no impact expected to GSK's credit rating.
• · GSK reaffirmed its 2026 dividend of 70p and progressive dividend policy.
• · GSK's FY 2026 guidance of 7-9% core operating profit and core EPS growth remains unchanged.
• · GSK expects low single-digit percentage dilution to core EPS for FY 2026, FY 2027, and FY 2028 from the transaction.
• · The acquisition is expected to be accretive to core operating profit in 2027 and core EPS in 2029 inclusive of synergies and reprioritisation.
• · Zidesamtinib has a target FDA decision date of 18 September 2026; neladalkib has a target decision date of 27 November 2026.
• · Both zidesamtinib and neladalkib have received FDA Breakthrough Therapy and Orphan Drug Designations.
• · The deal includes Nuvalent's preclinical portfolio of multiple programmes.

09-06-2026

Novanta Inc. announced a definitive agreement to acquire Riverpoint Medical for $1.2 billion upfront plus a $250 million milestone payment in Q1 2027, expected to close in Q3 2026. The acquisition is immediately accretive to Novanta's revenue growth, Adjusted Gross and EBITDA margins, Adjusted Diluted EPS, and Operating Cash Flows, and is projected to double recurring medical consumables revenue to approximately $300 million. However, the upfront purchase price of $1.2 billion represents approximately 19x Riverpoint's estimated 2026 Adjusted EBITDA excluding synergies, indicating a high valuation multiple, and the transaction will increase Novanta's net leverage ratio to approximately 2.7x post-closing.

• · Riverpoint Medical will be reported under Novanta's Medical Solutions operating segment.
• · Novanta expects net leverage ratio of approximately 2.7x after closing, reducing to below 2.3x by year-end 2027.
• · Transaction financed through cash on hand, existing credit facility, and a $300 million equity raise.
• · Novanta confirms its previously issued Q2 and Full Year 2026 financial guidance for the standalone company and will update guidance post-close.
• · Conference call scheduled for June 9, 2026 at 8:30 a.m. ET.
• · Riverpoint has manufacturing operations in Portland, Oregon and San Jose, Costa Rica.

09-06-2026

Nuburu, Inc. entered into a binding Head of Terms with SunCubes S.r.l. to invest up to €1,000,000 for a minority stake and establish an industrial cooperation framework for a vehicle-integrated directed-energy 'Laser Arm' system. The transaction is subject to Italian Golden Power clearance and export-control license clearance by December 30, 2026, and a capital increase condition by December 31, 2026. While the agreement opens strategic defense and energy technology opportunities, it carries significant execution risk as the definitive agreements and required clearances may not be obtained within the expected timeframe or at all.

• · The HoT is binding and was entered into on June 4, 2026.
• · SunCubes is an Italian developer of laser-based wireless power transmission and beam-control technologies.
• · Current Investors are venture capital vehicles affiliated with CDP Venture Capital, which is 70% owned by CDP Equity (part of the CDP group, majority-owned by the Italian Ministry of Economy and Finance).
• · Definitive Agreements must be entered into within 60 days of the HoT (by August 3, 2026).
• · Clearances must be obtained by December 30, 2026, or the Definitive Agreements automatically terminate.
• · If GP Clearance is granted only for the Industrial Cooperation Framework, parties will negotiate a joint venture structure.
• · The Capital Increase Condition requires conversion of the Current Investors' SAFE by December 31, 2026, triggered by a third-party capital increase of at least €1,230,000 or discretionary conversion by Current Investors.
• · If Clearances or Capital Increase Condition are not met, SunCubes must repay the Advance Payments to Nuburu by March 31, 2027.
• · Nuburu may designate an observer to SunCubes' Board of Directors upon attainment of Clearances.
• · SunCubes grants Nuburu a non-exclusive, fully paid-up license to certain background IP for specific fields and territories.
• · New IP arising from integration of SunCubes products will be retained by Nuburu, with a non-exclusive license back to SunCubes.
• · SunCubes agrees not to engage in activities related to anti-personnel mines or cluster munitions while CrossConnect or RoboIT are equity holders.
• · Nuburu's subsidiary Lyocon (wholly owned) and Tekne (70% owned subject to GP Clearance) are identified as potential industrialization sites in Italy.
• · The agreement includes a most-favored-customer pricing clause for Nuburu, with a potential additional discount up to 5% below the lowest price offered to other clients.

09-06-2026

Brand Engagement Network Inc. (BEN) entered into a definitive agreement on June 8, 2026, to form INTERVENT Health AI, Inc., a 50/50 healthcare AI joint venture with INTERVENT International, LLC. The JV will develop AI-powered health coaching solutions combining BEN's conversational AI with INTERVENT's clinically validated methodologies and datasets. BEN, through its subsidiary SKYE AI USA, will receive 35% of certain JV revenues from North American commercialization under a five-year exclusive arrangement, while the JV will receive 50% of gross revenues from proposed non-exclusive international reseller deals in Latin America and Africa. No financial performance metrics or revenue projections were disclosed, and the agreement is subject to performance milestones.

• · The JV's Board of Directors will consist of one BEN-appointed director, one INTERVENT-appointed director, and one mutually agreed independent director.
• · The Shareholder Agreement includes customary governance, pre-emptive rights, and ownership protection provisions, including restrictions on issuances that would reduce either founding shareholder below specified ownership thresholds without approval.
• · BEN is an emerging growth company as defined under SEC rules.
• · The agreement is subject to performance milestones for the five-year exclusive North American arrangement.

09-06-2026

22nd Century Group, Inc. filed an 8-K announcing stockholder approval of a 1-for-20 reverse stock split, effective at 12:01 a.m. on June 12, 2026. The reverse split reduces the number of issued and outstanding shares of common stock without adjusting par value or reducing authorized shares. Fractional shares will be rounded up to the nearest whole share.

• · Reverse stock split effective date: June 12, 2026 at 12:01 a.m.
• · Par value remains $0.00001 per share; authorized shares unchanged.
• · Fractional shares resulting from the split will be rounded up to the nearest whole share.
• · Old certificates will represent the post-split number of whole shares until surrendered.

09-06-2026

Aspira Women's Health Inc. entered into securities purchase agreements on June 5, 2026, for a private placement generating gross proceeds of approximately $1.485 million. The offering includes 3.3 million shares of common stock and warrants to purchase up to 4.455 million shares at an exercise price of $0.75 per share. Net proceeds will be used for working capital and general corporate purposes.

• · The common warrants are exercisable immediately upon issuance and have a term of three years.
• · The purchase agreement includes customary representations and warranties, conditions to closing, termination provisions, and an anti-dilutive provision.
• · The company granted purchasers customary registration rights for the shares and shares underlying the warrants.
• · The private placement was conducted with accredited and institutional investors.

09-06-2026

Soluna Holdings reported Q1 2026 revenue up 58% YoY, with Bitcoin hosting revenue up 178% YoY and a record hash rate, marking the fourth consecutive quarter of growth. However, the company also disclosed ongoing construction and development risks, including transformer repairs at Project Dorothy 1A that were completed in May, and noted that Project Kati 1B construction is still ongoing with Phase 3 ahead of schedule. The company regained Nasdaq compliance and signed a definitive JV agreement for Kati 2, but tenant due diligence and commercial negotiations remain in early stages.

• · Soluna regained compliance with Nasdaq listing requirements.
• · A definitive joint venture agreement was signed with Metrobloks for Kati 2, replacing the prior non-binding MOU.
• · A definitive purchase agreement was signed for 300 acres for Dorothy 3.
• · Briscoe Wind Farm (150 MW) was successfully integrated into operations.
• · Project Kati 1B Phase 1 (12 MW) achieved substantial completion; Phase 2 (9 MW) achieved mechanical and power commissioning; Phase 3 (14 MW) is ahead of schedule.
• · Project Annie (74 MW) is being developed for a potential new customer; ERCOT interconnection studies are nearing completion.
• · Tenant due diligence continues with Hyperscalers and Neoclouds; formal commercial negotiations started with at least one potential tenant for Kati 2.
• · The company engaged a top-tier investment bank to lead capital raising for Kati 2.
• · Transformer repair work at D1A was completed in May, returning operations to full capacity.

09-06-2026

Lisata Therapeutics entered into an amendment and waiver to its merger agreement with Kuva Labs, extending the offer commencement deadline and outside date, and receiving delayed interim operating payments totaling $250,000. The amendment also adds a representation by Parent regarding financial ability to fund the merger, including a non-binding indication of interest for up to $25 million in convertible notes. However, the lack of committed financing and the extension of deadlines introduce uncertainty about the merger's completion.

• · The original merger agreement was dated March 6, 2026.
• · The offer commencement deadline was extended from 60 business days after March 6 to 65 business days.
• · The outside date was extended from July 6, 2026 to July 17, 2026, with a possible further extension to August 17, 2026 upon payment of a $1.5 million extension fee.
• · Parent and Purchaser represent they have a reasonable, good faith belief that anticipated funding sources will be sufficient, but acknowledge no binding commitments exist.
• · The waiver includes a covenant not to sue during the waiver period (June 8 to June 10, 2026) and conditional waivers of claims related to delayed offer commencement and missed interim operating payment.
• · If Parent fails to make interim payments or commits a material breach, the Company may terminate Sections 2, 3, and 4 of the waiver.

09-06-2026

Rain Enhancement Technologies Holdco, Inc. entered into a debt-to-equity conversion agreement with RHY Management LLC, an affiliate of Chairman Harry You, converting $4,000,000 of outstanding debt into 1,612,903 shares of Class A common stock at $2.48 per share. The company also issued 50,000 shares to its interim CFO and 490,000 shares to directors, advisors, and a consultant as compensation. Following these issuances, total outstanding Class A common stock reached 10,283,984 shares as of June 5, 2026.

• · The conversion price was set at $2.48 per share, based on the 10-day VWAP preceding June 5, 2026.
• · The converted debt of $4,000,000 is part of a larger outstanding debt of approximately $12,300,000 under the Loan Agreement.
• · The original Loan Agreement included a $3,064,403.66 rollover loan and a line of credit initially set at $7,000,000, later increased to $10,000,000 as of March 31, 2026.
• · Shares issued to RHY Management LLC are subject to a lock-up agreement until the earlier of December 31, 2026 or a liquidity event.
• · The company relied on Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D for the unregistered sale of equity securities.
• · The company is an emerging growth company and has not elected to use the extended transition period for complying with new financial accounting standards.

09-06-2026

VerifyMe, Inc. entered into the Second Amendment to its Merger Agreement with Open World Ltd. on June 4, 2026, revising the definition of Fully Diluted Company Shares to include shares issuable under existing equity agreements. This amendment is part of the previously disclosed merger through which Open World will become a wholly-owned subsidiary of VerifyMe.

• · The Merger Agreement was previously disclosed and originally involved Merger Sub merging with and into Open World.
• · The Second Amendment revises the definition of Fully Diluted Company Shares to include Open World ordinary shares issuable under any existing agreement to issue Equity Interests.
• · The Amendment is filed as Exhibit 2.1 and incorporated by reference from the Company’s Registration Statement on Form S-4/A filed on June 8, 2026.
• · The filing is a written communication pursuant to Rule 425 under the Securities Act.

09-06-2026

Ingredion announced a recommended all-cash acquisition of Tate & Lyle for a total enterprise value of approximately £3.7B ($5.0B), representing a 59% premium to Tate & Lyle's closing share price as of May 13, 2026. The deal is expected to deliver significant net cost synergies of approximately $130 million annually by 2030, with one-time integration costs of about $175 million. Completion is expected in the second half of 2027, subject to shareholder and regulatory approvals.

• · Ingredion intends to finance the acquisition through existing cash, new debt, and a fully committed bridge facility.
• · Pro forma net leverage at completion expected to be approximately 3.0x net debt-to-adjusted EBITDA, with a target to reduce to ~2.5x within 18 months post-completion.
• · Tate & Lyle shareholders will also receive a final dividend of up to 13.2 pence per share for FY ended March 31, 2026, and an interim dividend of up to 6.8 pence per share for H1 ending September 30, 2026.
• · The acquisition is expected to be adjusted EPS accretive in the first year following completion.
• · The transaction has been unanimously approved by Ingredion's Board of Directors and is recommended unanimously by Tate & Lyle's Board.
• · Completion is subject to Tate & Lyle shareholder approval, court sanction, and antitrust conditions.

09-06-2026

NexPoint Residential Trust, Inc. (NXRT) reported Q3 2025 results with net income of $0.8 million, or $0.03 per diluted share, compared to net income of $1.3 million, or $0.05 per diluted share, in Q3 2024. Core FFO was $0.47 per diluted share, down from $0.50 in the prior year quarter. Same-store revenue increased 2.0% year-over-year, while same-store expenses rose 3.5%, resulting in a 1.0% increase in same-store NOI. The company also announced a quarterly dividend of $0.375 per share.

• · Quarterly dividend declared of $0.375 per share.
• · Same-store occupancy was 94.5% at quarter end.
• · Acquired one property for $45.0 million during the quarter.

09-06-2026

AXT INC filed an 8-K on June 9, 2026, reporting amendments to its charter/bylaws (Item 3.03), changes in its controlling shareholder or directors (Item 5.03), and shareholder vote results (Item 5.07). The filing does not contain any financial results or quantitative performance data, so no period-over-period comparisons are available.

• · The filing is a Current Report (8-K) covering Items 3.03, 5.03, 5.07, and 9.01.
• · The filing date is June 9, 2026.
• · The company is incorporated in Delaware and headquartered in Fremont, California.
• · The SIC code is 3674 (Semiconductors & Related Devices).

09-06-2026

Cheniere Energy Partners, L.P. (CQP) entered into a Registration Rights Agreement on June 9, 2026, in connection with the issuance of $1.75 billion aggregate principal amount of senior notes: $1.0 billion of 5.350% Senior Notes due 2036 and $750 million of 6.050% Senior Notes due 2056. The agreement obligates the company to file an exchange offer registration statement within 360 days of the issue date and, under certain conditions, a shelf registration statement, providing liquidity and tradability for the notes. The notes are guaranteed by several subsidiaries, including Cheniere Energy Investments, Sabine Pass LNG entities, and Cheniere Creole Trail Pipeline.

• · The Registration Rights Agreement was entered into as an inducement for the Purchasers to enter into the Purchase Agreement dated May 26, 2026.
• · The notes are issued under a Base Indenture dated September 18, 2017, as supplemented by the Eleventh and Twelfth Supplemental Indentures dated June 9, 2026.
• · The company must use commercially reasonable efforts to keep the Exchange Offer Registration Statement effective for at least 20 business days after notice is mailed to holders.
• · If the Registered Exchange Offer is not consummated within 360 days of the issue date, or if certain other conditions are met, the company must file a Shelf Registration Statement.
• · Holders participating in the exchange offer must represent they are acquiring the Exchange Securities in the ordinary course of business and have no arrangements to distribute them.

09-06-2026

Big Digital Energy, Inc. (Nasdaq: BGDE) announced the termination of its stockholder rights agreement, effective June 8, 2026, after the Board concluded it is no longer necessary. The company operates 129 MW of digital infrastructure capacity and focuses on carbon-free energy sources including nuclear power.

• · The Rights Agreement was originally set to expire on February 1, 2027, but was accelerated to June 8, 2026.
• · The Board unanimously approved the amendment to accelerate expiration.
• · The company provides services for AI, HPC, digital assets (including Bitcoin mining), and other intensive compute applications.
• · The company's strategy includes powering operations with carbon-free energy resources, including nuclear power.
• · The company has 129 megawatts of capacity already online and more under development.

09-06-2026

Affiliated Managers Group, Inc. entered into a Fourth Amended and Restated Credit Agreement dated June 9, 2026, establishing a $1.25 billion revolving credit facility with Bank of America as administrative agent and a syndicate of lenders. The agreement amends and restates the prior Third Amended and Restated Credit Agreement dated November 15, 2024, and includes provisions for alternative currency loans, increased commitments, and various financial covenants.

• · The credit agreement is dated June 9, 2026 and amends and restates the Third Amended and Restated Credit Agreement dated November 15, 2024.
• · The facility includes a swingline lender and L/C issuer (Bank of America) and allows for alternative currency loans in Euro, Sterling, and Canadian Dollar.
• · The agreement includes financial condition covenants, limitations on priority debt and liens, and events of default provisions.

09-06-2026

Aditxt, Inc. entered into a Note Purchase Agreement on June 3, 2026, issuing $725,000 in new senior secured convertible notes (plus consolidation of existing notes) to investors, with a 35% original issue discount. The subsidiary Ignite Proteomics LLC granted a security interest in substantially all its assets, and Aditxt pledged its equity in Ignite as collateral. The filing also includes representations that the company is not insolvent and has no undisclosed material adverse events, but the heavy discount and reliance on secured debt highlight significant financial strain.

• · The new Notes consolidate $3,194,444.44 in Existing March Notes (10% OID) and $1,250,000 in Existing April Notes (25% OID).
• · Ignite Proteomics LLC granted a security interest in substantially all its assets as collateral.
• · Aditxt pledged its equity in Ignite Proteomics LLC as collateral.
• · The offering is exempt from registration under Section 4(a)(2) and Rule 506(b) of Regulation D.
• · The filing includes representations that the company is not insolvent and has no undisclosed material adverse events.

09-06-2026

Arch Capital Group Ltd. completed a public offering of $2.0 billion in senior notes on June 9, 2026, consisting of $600 million of 5.250% notes due 2036 and $1.4 billion of 5.950% notes due 2056. The notes are senior unsecured obligations and are not guaranteed by any subsidiaries. Interest will be paid semi-annually starting December 15, 2026.

• · The notes were issued under a base indenture dated May 4, 2004, supplemented by a Third Supplemental Indenture dated June 9, 2026.
• · The 2036 notes mature on June 15, 2036; the 2056 notes mature on June 15, 2056, subject to deferral if regulatory capital requirements are not met.
• · Redemption provisions include make-whole redemption prior to March 15, 2036 (2036 notes) and prior to December 15, 2055 (2056 notes), and par redemption on or after those dates.
• · The notes are effectively subordinated to all secured indebtedness and to all obligations of the issuer's subsidiaries.
• · The offering was made under a universal shelf registration statement on Form S-3 (File No. 333-275570).

09-06-2026

Cheniere Energy Partners, L.P., a subsidiary of Cheniere Energy, Inc., closed a private placement of $1.0 billion aggregate principal amount of 5.350% Senior Notes due 2036 and $750 million aggregate principal amount of 6.050% Senior Notes due 2056 on June 9, 2026. The notes are senior unsecured obligations guaranteed by certain subsidiaries and were issued under supplemental indentures to the base indenture dated September 18, 2017. The company also entered into a Registration Rights Agreement with BofA Securities, Inc. to use commercially reasonable efforts to register the notes for exchange within 360 days.

• · The notes were issued in a private placement under Section 4(a)(2) of the Securities Act and Rule 144A/Regulation S.
• · Interest on both tranches is payable semi-annually on May 30 and November 30, beginning November 30, 2026.
• · The 2036 Notes mature on November 30, 2036; the 2056 Notes mature on November 30, 2056.
• · Cheniere Partners may redeem the notes at any time prior to the Applicable Par Call Date (May 30, 2036 for 2036 Notes; May 30, 2056 for 2056 Notes) at a make-whole redemption price, and at par thereafter.
• · The notes are senior unsecured obligations ranking equally with existing and future unsubordinated debt and senior to future subordinated debt.
• · The Registration Rights Agreement requires Cheniere Partners to use commercially reasonable efforts to file an exchange offer registration statement within 360 days of the Issue Date, with additional interest payable for non-compliance.

09-06-2026

HWH International Inc. entered into a $10M PIPE with Smart Dynamics Technology Limited for 20M shares and warrants for 160M shares at $0.63 per share, and simultaneously completed a $500,000 stock purchase by majority shareholder Alset Inc. at $2.00 per share. The PIPE closing is subject to stockholder approval and Nasdaq extension, while Alset's investment closed on June 9, 2026, increasing its ownership from 79.8% to 80.5%. The transactions highlight significant insider involvement and reliance on regulatory approvals.

• · The PIPE warrants have an exercise price of $0.63 per share and expire on the fourth anniversary of closing.
• · The Amendment to the Securities Purchase Agreement added a closing condition requiring Nasdaq extension for continued listing compliance.
• · Alset's investment of $500K at $2.00 per share closed on June 9, 2026.
• · The PIPE is subject to stockholder approval by a majority of common stock holders.
• · The securities were issued under exemption from registration under Section 4(a)(2) and Rule 506 of Regulation D.
• · Chan Heng Fai is Chairman, CEO and majority stockholder of Alset; four other HWH board members are also Alset directors; two HWH officers are also Alset officers/directors.

09-06-2026

Cycurion, Inc. completed the acquisition of Secuvant, LLC and its Panoptic cybersecurity platform on June 2, 2026, for total consideration of approximately $2.875 million, consisting of $875,000 in cash and 888,888 shares of preferred stock valued at about $2.0 million. The deal includes contingent earn-out payments over three years (2026-2028) with guaranteed annual payments of $100,000 and additional performance-based payments tied to gross profit, paid 50% in cash and 50% in common stock. While the acquisition is expected to expand Cycurion's higher-margin recurring revenue portfolio and create cross-selling opportunities, the company faces integration risks and the earn-out structure introduces uncertainty around future cash flows.

• · Merger agreement was signed on May 21, 2026, and closed on June 2, 2026.
• · Secuvant equityholders are eligible for contingent earn-out payments over three years (2026-2028) with guaranteed annual payments of $100,000.
• · Performance-based earn-out payments are tied to gross profit from certain revenue streams and paid 50% in cash and 50% in Cycurion common stock.
• · Ancillary agreements include registration rights, lock-up, leak-out, and escrow arrangements.
• · Ryan Layton now serves as an advisor to Cycurion for integration of Secuvant business.

09-06-2026

Global Technologies, LTD (GTLL) reported revenue of $642,822 for the nine months ended March 31, 2026, with cash and cash equivalents of $38,178. The company is repositioning from a wholesale model to a relationship-driven operating platform, having opened relationships with over 150 cash-pay clinics and 20 small businesses since October 2025. However, the company remains undercapitalized with working capital constraints, and its revenue recognition model has shifted to net revenues, with Primecare Supply generating only $71,581 in net revenue on $404,625 in gross product sales for the quarter.

• · GTLL filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 on June 3, 2026.
• · The company appointed William 'Bill' Norton to its Board of Directors and entered into an amended executive and board member agreement.
• · Three shares of Series K Super Voting Preferred Stock were issued to CEO H. Wyatt Flippen for governance continuity.
• · A new Series R Preferred Stock designation was adopted, authorizing 250,000 shares with defined voting, conversion, and transfer provisions.
• · GTLL entered into a Binding Letter of Intent regarding FORCARA, a potential subsidiary expansion, subject to further diligence and closing conditions.
• · The company's revenue recognition model was adjusted to reflect net revenues instead of gross revenues due to its singular role in procurement.
• · Ordering patterns for Primecare are described as 'not yet linear' with month-to-month fluctuations.
• · The company remains undercapitalized and faces working capital constraints that may limit the pace of corporate initiatives.

09-06-2026

Redwire Corporation entered into a new Equity Distribution Agreement (June 2026 ATM Agreement) on June 9, 2026, allowing the sale of up to $500 million in common stock through multiple agents. The company terminated its prior May 2026 ATM Agreement without penalties. Proceeds will be used for working capital, debt repayment, acquisitions, and R&D.

• · The June 2026 ATM Agreement replaces the prior May 2026 ATM Agreement, which was terminated on June 9, 2026 with no penalties.
• · Shares will be sold under a shelf registration statement (Form S-3ASR, File No. 333-289380) filed August 7, 2025.
• · The company may sell shares through agents as principal or in block trades, with a commission of up to 3% of gross sales price.
• · The agreement automatically terminates upon issuance and sale of all shares, but can be terminated earlier by either party with written notice.
• · The legal opinion and consent from Sheppard, Mullin, Richter & Hampton LLP are filed as Exhibits 5.1 and 23.1.

09-06-2026

Professional Diversity Network, Inc. (IPDN) received a Nasdaq deficiency notice on June 5, 2026, for failing to meet the minimum bid price requirement of $1.00 per share over 30 consecutive business days. The company has a 180-day compliance period until December 2, 2026, to regain compliance, and may qualify for a second 180-day period if needed. While management is evaluating measures to address the deficiency, there is no assurance of regaining compliance or avoiding delisting.

• · The company's common stock has a par value of $0.01 per share.
• · If compliance is not achieved by December 2, 2026, the company may be eligible for a second 180-day compliance period, subject to meeting other listing standards.
• · The company may appeal any delisting determination to a Nasdaq hearings panel.
• · The company's current liquidity position and need for additional financing are noted as risks.

09-06-2026

Sherwin-Williams entered into Amendment No. 11 to its Amended and Restated Credit Agreement, extending the maturity of $200,000,000 of commitments from June 20, 2026 to June 20, 2031. The amendment was executed with Goldman Sachs Bank USA as administrative agent and Goldman Sachs Mortgage Company as issuing bank. This extension provides the company with longer-term liquidity and financial flexibility.

• · The original Credit Agreement was dated August 2, 2021.
• · The amendment extends $200,000,000 of commitments from June 20, 2026 to June 20, 2031.
• · Goldman Sachs Bank USA serves as administrative agent; Goldman Sachs Mortgage Company serves as issuing bank.
• · Certain lenders and affiliates have performed and may continue to perform various financial services for Sherwin-Williams and its subsidiaries.

09-06-2026

Jasper Therapeutics received a Nasdaq deficiency notice on June 3, 2026, because its common stock bid price closed below $1.00 for 30 consecutive business days. The company has 180 days (until November 30, 2026) to regain compliance, and may be eligible for an additional 180-day period if it meets other listing standards. There is no immediate impact on trading, and management is evaluating options including a potential reverse stock split, though compliance is not assured.

• · The company's common stock (JSPR) and warrants (JSPRW) continue trading on the Nasdaq Capital Market without immediate disruption.
• · If not compliant by Nov. 30, 2026, an additional 180-day period may be available if the company meets other initial listing standards and provides written notice of intent to cure (e.g., via reverse stock split).
• · Jasper is an emerging growth company and has not elected to use the extended transition period for new accounting standards.
• · The warrants have an exercise price of $115.00 per share (10 warrants for one share).

09-06-2026

Medalist Diversified REIT, Inc. (MDRR) entered into a Purchase and Sale Agreement on June 8, 2026 to acquire a 1.64-acre automotive service property in Overland Park, Kansas for $5.8 million. The company plans to assign the agreement to a newly formed Delaware statutory trust (DST) and raise capital from accredited investors via a Regulation D private placement to fund the acquisition. The transaction is expected to close within 45 days, subject to customary conditions, and there is no assurance of completion.

• · The property is located at 14939 Metcalf Avenue, Overland Park, Kansas, consisting of 1.64 acres and an approximately 16,100 square foot automotive service building.
• · The earnest money deposit of $150,000 is due within three business days of the Effective Date (June 8, 2026).
• · The Company intends to assign its interests in the Agreement to a to-be-formed Delaware statutory trust (DST) and complete the acquisition through the DST.
• · Proceeds from the private placement of DST beneficial interests will be used to redeem the Company’s beneficial interests for cash.
• · Closing is expected within 45 days, but there is no assurance the transaction will be completed.
• · Under certain conditions, the Deposit may not be returned to the Company.

09-06-2026

PennantPark Private Income Fund increased its senior secured revolving credit facility from $120.0 million to $200.0 million via a second amendment dated June 5, 2026. The amendment expands borrowing capacity by $80.0 million, or 66.7%, while leaving all other material terms unchanged. No negative or flat metrics are present in this filing.

• · The amendment was entered into on June 5, 2026, and filed on June 9, 2026.
• · The borrower is PennantPark Private Income Fund SPV, LLC, a wholly-owned subsidiary of PennantPark Private Income Fund.
• · The collateral manager is PennantPark Investment Advisers, LLC.
• · The administrative agent is CIBC Bank USA.
• · The collateral agent is Western Alliance Trust Company, National Association.
• · No other material terms of the Credit Facility were modified.

09-06-2026

Edgemode, Inc. entered into a securities purchase agreement with an accredited investor on June 3, 2026, issuing a convertible promissory note with a principal amount of $300,000, an original issuance discount of $50,000, and net proceeds of $250,000 for working capital. The note matures on August 3, 2026, and carries a 12% annual interest rate with a conversion price of $0.01 per share, subject to potential resets to lower prices if the stock trades below certain thresholds. The note includes standard events of default, a 9.99% ownership limitation, and restrictions on senior borrowings.

• · The note matures on August 3, 2026, indicating a very short-term maturity of about two months.
• · Conversion price is $0.01 per share initially, with potential resets to $0.0075 per share or lower if stock price declines.
• · The note was issued in a private placement relying on Section 4(a)(2) exemption from registration.
• · The company received only $250,000 in net proceeds after a $50,000 discount, implying immediate effective interest cost of 20% at issuance.
• · The filing does not disclose the name of the accredited investor.

09-06-2026

LiqTech International announced the pricing of a $20 million underwritten public offering of 20,000,000 shares at $1.00 per share, expected to close June 8, 2026. Net proceeds will repay approximately $4.1 million of senior notes and fund business development and working capital. However, the substantial dilution to existing shareholders from issuing 20 million new shares (plus potential overallotment of 3M shares) is a significant negative factor, and the company's need to raise capital suggests ongoing cash burn.

• · Offering price: $1.00 per share
• · Underwriter: Konik Capital Partners, LLC (division of T.R. Winston & Company, LLC) as sole book-running manager
• · Over-allotment option: 45 days, up to 3,000,000 additional shares at public offering price less discounts
• · Offering is pursuant to an effective S-1 registration statement (File No. 333-296258) declared effective June 1, 2026
• · Use of proceeds: repay ~$4.1M senior notes, invest in business development, fund working capital, and general corporate activities
• · Company is a clean technology company specializing in advanced ceramic filtration solutions (Silicon Carbide membranes)
• · Headquarters: Ballerup, Denmark; founded in 2000
• · Risk factors referenced from 2025 10-K and Q1 2026 10-Q

09-06-2026

Super League Enterprise, Inc. (SLE) entered into a Redemption Agreement with Yield Point NY, LLC to redeem all 1,153 shares of Series C Convertible Preferred Stock for a discounted price of $922,400 (80% of the $1,153,000 stated value) and to terminate the $20,000,000 Equity Line of Credit (ELOC) arrangement. The redemption price includes a $1,000 legal fee, and the agreement was subject to payment by June 8, 2026. This transaction reduces SLE's debt-like obligations and eliminates a potential dilutive equity facility, but the discount implies a loss for the holder and may signal financial constraints.

• · The redemption price of $922,400 represents an 80% discount to the stated value of $1,153,000, implying a $230,600 loss for the holder.
• · The ELOC arrangement, which provided up to $20,000,000 in potential equity financing, is terminated with no outstanding draw requests.
• · The agreement includes mutual releases of claims between SLE and Yield Point NY, LLC related to the redeemed shares and the ELOC.
• · The redemption was subject to a deadline of June 8, 2026; if not paid by then, the agreement would be null and void.
• · Yield Point NY, LLC retains a warrant issued contemporaneously with the Series C Preferred Stock, which is not affected by this redemption.